Inventor
BLACKLOCK THOMAS J
US17 patents
⚠️ This page may combine multiple inventors who share the name “BLACKLOCK THOMAS J”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
MERCK & CO INC
10 patentsUS4510083AApr 9, 1985
Process for preparing polypeptides
MERCK & CO INC33 citations92
US5157129AOct 20, 1992
Enantiospecific synthesis of s-(+)-5,6-dihydro-4-(r-amino)-4h-thieno(2,3-b)thiopyran-2-sulfonamide-7,7-dioxide
MERCK & CO INC23 citations90
US5189177AFeb 23, 1993
Chiral boron catalysts for reduction of ketones and process for their preparation
MERCK & CO INC19 citations81
US5039802AAug 13, 1991
Arylation process for preparation of chiral catalysts for ketone reduction
MERCK & CO INC20 citations81
US5688968ANov 18, 1997
Enantioselective synthesis of 5,6-dihydro-(S)-4-(ethylamino)-(S)-6-methyl-4H-thieno 2,3-B!thiopyran-2-sulfonamide 7,7-dioxide
MERCK & CO INC14 citations73
US5264585ANov 23, 1993
Chiral catalysts for reduction of ketones and process for their preparation
MERCK & CO INC15 citations73
US4968815ANov 6, 1990
Synthesis of (S)-3-(thien-2-ylthio)butyric acid analogs
MERCK & CO INC11 citations73
US4968814ANov 6, 1990
(S)-Alkyl 3-(thien-2-ylthio)butyrate and analogs and synthesis thereof
MERCK & CO INC15 citations73
US4992541AFeb 12, 1991
Process for the preparation of 1,1-dioxo-7-substituted cephems
MERCK & CO INC10 citations69
US5011942AApr 30, 1991
Process for racemizing an enantiomer of 5,6-dihydro-4-alkylamino-4H-thieno(or furo) [2,3-B]-thiopyran-2-sulfonamide-7,7-dioxide
MERCK & CO INC4 citations62
JOHNSON MATTHEY PLC
3 patentsUS5612478AMar 18, 1997
Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
JOHNSON MATTHEY PLC45 citations94
US5801281ASep 1, 1998
Process for preparing 1,1'- (1,4- phenylenebis (methlene)-Bis 1,4,8,11-tetraazacyclotetradecane
JOHNSON MATTHEY PLC22 citations91
US5756728AMay 26, 1998
Process for preparing 1,1'- 1,4-phenylenebis-(methylene)!-bis-1,4,8,11-tetraazacyclotetradecane
JOHNSON MATTHEY PLC19 citations91
FENG LILI
2 patentsUS8877938B2Nov 4, 2014
Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
FENG LILI44 citations95
US9388134B2Jul 12, 2016
Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
FENG LILI5 citations81
NOVARTIS PHARMACEUTICALS CORP
2 patentsUS11642329B2May 9, 2023
Amorphous solid form of compounds containing S—N-valeryl-N- {[2′-( 1 H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations
NOVARTIS PHARMACEUTICALS CORP0 citations60
US11096918B2Aug 24, 2021
Amorphous solid form of compounds containing S—N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations
NOVARTIS PHARMACEUTICALS CORP0 citations60